HCW Biologics
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2018-04-01
- Employees
- 45
- Market Cap
- -
- Website
- http://www.hcwbiologics.com
- Introduction
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
HCW Biologics Secures $5 Million in Follow-On Financing to Advance Immunotherapy Pipeline
HCW Biologics has successfully raised $5 million in a follow-on offering to fund clinical development of its novel immunotherapies targeting inflammation-related diseases, particularly its Phase 1 trial of HCW9302 for autoimmune disorders.
HCW Biologics' Novel Fusion Protein Shows Promise for Revolutionizing CAR-T Cell Production
HCW Biologics' proprietary fusion protein HCW9206 demonstrates superior efficacy in generating CAR-T cells with enhanced function and persistence compared to standard methods.
HCW Biologics' HCW9302 Receives FDA Clearance for Phase 1 Alopecia Areata Trial
HCW Biologics received FDA clearance for its IND application to begin a Phase 1 trial of HCW9302 in moderate-to-severe alopecia areata patients.